Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ResMed (RMD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read about ResMed, Abbott Laboratories and more in the latest Market Talks covering the Health Care sector.

Shares of ResMed Inc. RMD shed 1.16% to $211.49 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

Mizuho analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $265 from $280 and keeps an Outperform rating on the shares ...

ResMed Inc. closed 18.65% short of its 52-week high of $263.05, which the company reached on January 30th.

Morgan Stanley analyst David Bailey maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – ...

ResMed shares have been caught up in the recent market volatility. Has this created a buying window for ResMed shares?

Trump's universal 10% tariffs will impact healthcare names like Ansell and ResMed, while Cochlear, Ramsay and Sonic Healthcare face no direct exposure Ansell may need a 6-7% price hike to offset ...

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Resmed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market ...